Tests NBI-1117570 against placebo in hospitalized adults with schizophrenia
Tests NBI-1117570 or a placebo in adults with schizophrenia needing hospital care.
Plain-language title generated from the registry record
Registry title: Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
Key facts
- Where
- Bialystok, Gdansk, Lodz, and Poznan, PolandSee the 4 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with schizophrenia who are having a sudden worsening of symptoms and need to be in hospital.
- Age
- 18 to 55 years
- Sex
- All sexes can join.
- Disease stage
- Diagnosis of schizophrenia at least 1 year before screening. Sudden worsening or relapse that began less than 2 months before screening, with a current need for hospital care.
- Earlier treatment
- Must have had a positive response to at least 1 antipsychotic medicine (other than clozapine) for an earlier acute relapse. Cannot be taking prohibited medicines.
Main reasons for not taking part
- Imminent risk of suicide or of harming self or others
- History of epilepsy, seizures or convulsions
- Certain heart or blood pressure conditions, such as orthostatic hypotension, heart failure or past heart attack
- Taking prohibited medicines
- Pregnant or breastfeeding
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT07288333, who can take part
Where in Poland
- Uniwersytecki Szpital Kliniczny w BialymstokuBialystok, PolandNot yet recruiting
- Uniwersyteckie Centrum KliniczneGdansk, PolandNot yet recruiting
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Centralny Szpital Kliniczny Uniwersytetu Medycznego W LodziLodz, PolandNot yet recruiting
- Centrum Medyczne HCP Sp. z o.o.Poznan, PolandNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Neurocrine Biosciences
- Trial code
- NCT07288333EU 2025-521868-35-00
- Record updated
- 22 July 2026
- Original description
The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.Read full original descriptionShow less
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.
Inclusion: 18 to 55 years of age; Primary diagnosis of schizophrenia ≥1 year before screening; Participant is experiencing an acute exacerbation or relapse of symptoms with onset less than 2 months before screening and currently requires hospitalization; Participant must have had a positive response to at least 1 antipsychotic therapy (other than clozapine) for the treatment of a prior acute relapse.
Exclusion: Currently taking prohibited medications; History of epilepsy, seizures, or convulsions; Has orthostatic hypotension, or history of pulmonary hypertension, obstructive coronary artery disease, hypertrophic cardiomyopathy, myocardial infarction, coronary artery revascularization, heart failure, left ventricular hypertrophy, moderate or severe cardiac valvopathy, or other cardiovascular conditions or measures that would preclude participation; Considered to be at imminent risk of suicide or injury to self or others; Pregnant or lactating; Note: Additional inclusion/exclusion criteria may apply, per protocol.